PA8581801A1 - Formulaciones que contienen un compuesto de indolinona - Google Patents

Formulaciones que contienen un compuesto de indolinona

Info

Publication number
PA8581801A1
PA8581801A1 PA20038581801A PA8581801A PA8581801A1 PA 8581801 A1 PA8581801 A1 PA 8581801A1 PA 20038581801 A PA20038581801 A PA 20038581801A PA 8581801 A PA8581801 A PA 8581801A PA 8581801 A1 PA8581801 A1 PA 8581801A1
Authority
PA
Panama
Prior art keywords
formulations containing
indolinone compound
formulations
same
indolinone
Prior art date
Application number
PA20038581801A
Other languages
English (en)
Inventor
Paolo Gatti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8581801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of PA8581801A1 publication Critical patent/PA8581801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION PRESENTA FORMULACIONES DE INDOLINONAS. LA FORMULACION ES INDICADA PARA ADMINISTRACION PARENTERAL U ORAL, EN DONDE LA FORMULACION CONTIENE UNA INDOLINONA Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE DEL MISMO. LAS FORMULACIONES Y LOS COMPUESTOS POR SI MISMOS SON PROVECHOSOS PARA EL TRATAMIENTO DE LAS ENFERMEDADES RELACIONADAS CON LA PROTEINA QUINASA.
PA20038581801A 2002-09-10 2003-09-10 Formulaciones que contienen un compuesto de indolinona PA8581801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10

Publications (1)

Publication Number Publication Date
PA8581801A1 true PA8581801A1 (es) 2005-02-04

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038581801A PA8581801A1 (es) 2002-09-10 2003-09-10 Formulaciones que contienen un compuesto de indolinona

Country Status (31)

Country Link
US (1) US20040229930A1 (es)
EP (1) EP1536783B2 (es)
JP (1) JP2006503032A (es)
KR (1) KR20050059170A (es)
CN (1) CN1688304A (es)
AR (1) AR041193A1 (es)
AT (1) ATE403425T1 (es)
AU (1) AU2003280108B2 (es)
BR (1) BR0314182A (es)
CA (1) CA2498415C (es)
DE (1) DE60322720D1 (es)
DK (1) DK1536783T3 (es)
DO (1) DOP2003000708A (es)
ES (1) ES2309363T5 (es)
GT (1) GT200300193A (es)
HN (1) HN2003000272A (es)
MX (1) MXPA05002690A (es)
MY (1) MY136767A (es)
NL (1) NL1024261C (es)
NO (1) NO20051670L (es)
NZ (1) NZ538636A (es)
PA (1) PA8581801A1 (es)
PE (1) PE20040989A1 (es)
PL (1) PL375978A1 (es)
PT (1) PT1536783E (es)
RU (1) RU2005110663A (es)
SI (1) SI1536783T1 (es)
TW (1) TW200418836A (es)
UY (1) UY27969A1 (es)
WO (1) WO2004024127A2 (es)
ZA (1) ZA200501897B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4933259B2 (ja) * 2003-10-02 2012-05-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロール置換インドリノン化合物の塩および多形
CA2622870A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA2699306A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010039798A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
DK2844282T3 (da) 2012-05-04 2019-07-15 Pfizer Prostata-associerede antigener og vaccine-baserede immunterapiregimener
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EA202191904A1 (ru) * 2019-01-09 2021-10-04 Селджин Корпорейшн Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
EP1233943B1 (en) * 1999-11-24 2011-06-29 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
CN1329390C (zh) * 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
ES2453164T3 (es) * 2001-08-15 2014-04-04 Pharmacia & Upjohn Company Llc Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
TWI259081B (en) † 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
DK1536783T3 (da) 2008-10-13
WO2004024127A2 (en) 2004-03-25
GT200300193A (es) 2004-04-29
HN2003000272A (es) 2008-07-29
RU2005110663A (ru) 2005-09-10
AR041193A1 (es) 2005-05-04
CA2498415C (en) 2007-05-29
ATE403425T1 (de) 2008-08-15
CN1688304A (zh) 2005-10-26
ZA200501897B (en) 2005-09-07
AU2003280108B2 (en) 2007-04-05
UY27969A1 (es) 2004-04-30
NZ538636A (en) 2006-04-28
CA2498415A1 (en) 2004-03-25
MY136767A (en) 2008-11-28
NO20051670L (no) 2005-04-04
EP1536783B2 (en) 2011-08-24
PT1536783E (pt) 2008-10-10
KR20050059170A (ko) 2005-06-17
NL1024261C (nl) 2010-04-06
PE20040989A1 (es) 2004-12-28
WO2004024127A3 (en) 2004-06-03
MXPA05002690A (es) 2005-05-05
ES2309363T3 (es) 2008-12-16
DE60322720D1 (de) 2008-09-18
JP2006503032A (ja) 2006-01-26
ES2309363T5 (es) 2011-12-07
US20040229930A1 (en) 2004-11-18
NL1024261A1 (nl) 2004-03-11
BR0314182A (pt) 2005-08-09
EP1536783A2 (en) 2005-06-08
PL375978A1 (en) 2005-12-12
SI1536783T1 (sl) 2008-12-31
EP1536783B1 (en) 2008-08-06
TW200418836A (en) 2004-10-01
AU2003280108A1 (en) 2004-04-30
DOP2003000708A (es) 2004-03-31

Similar Documents

Publication Publication Date Title
PA8581801A1 (es) Formulaciones que contienen un compuesto de indolinona
UY26782A1 (es) Derivados del benzotiazol
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CO5271700A1 (es) Composicion farmaceutica que comprende acido 3-[2,4-dimetil-5-(2-oxo-1,2-dihidro-indol-3-ilidenmetil)-1h-pirrol-3-il]-propionico, uno o mas compuestos polihidrocarbilo y un vehiculo farmaceuticamente aceptable
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
CO5590918A2 (es) Formulaciones
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
UY27553A1 (es) Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
NO20063429L (no) Brusende oral opiat doseringsform
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
PA8583301A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
BR0208382A (pt) Forma de dosagem oral contendo nicotina
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
DK1251846T3 (da) C4-Carbonattaxaner
DE60214476D1 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina